Monday, September 13, 2010
Advances in peptides and nucleic acids synthesis, areas where Bio Synthesis has over twenty years of experience, have promoted the development of bioconjugates where these molecules are either cross-linked to each other or to other compounds to yield products with distinct properties. Bio Synthesis, benefiting of its expertise in peptides and nucleic acids synthesis, is developing new methods for the efficient production of bioconjugates.
Taking advantage of its expertise in nucleic acids and peptide synthesis, BioSynthesis is developing new approaches for the production of different bioconjugates. From the point of view of therapeutic applications, because of their potential uses in genetic therapy and blocking gene expression the bioconjugates of nucleic acids are the most important ones.
Properties of Bioconjugates
In general these bioconjugates acquire new properties, such as resistance to degradation and passage of the hydrophilic and anionic oligonucleotide across the hydrophobic negatively charged cell membrane or transduction. Yet, a suitable bioconjugate should maintain practically all of the oligonucleotide’s biological properties.
Oligonucleotide moiety of Bioconjugate
This moiety or cargo of the bioconjugate can be either a DNA/ODN or a RNA/ORN. Because of their anionic nature they cannot pass across cell membranes unless they are conjugated to a CPP. Peptide-DNA conjugates are used in genetic therapy to replace a defective gene or alternatively to inhibit the expression of a specific gene by antisense DNA.